HomeBUSINESS
BUSINESS

DS-8201 Data Out for Multiple HER2-Expressing Tumors: Daiichi Sankyo
(Sep.13.2017)

Daiichi Sankyo’s HER2-targeting antibody drug conjugate (ADC) DS-8201 showed antitumor activity with multiple HER2-expressing tumors, including colon cancer and non-small cell lung cancer (NSCLC), according to preliminary PI data ...
(LOG IN FOR FULL STORY)

News Calendar